The predecessor of Phil Gregory as CSO of Bluebird Bio (BLUE) Mitchell Finer is now Managing Director of MPM Capital.
MPM’s Managing Director Todd Foley states: “The focus of our latest fund is to achieve breakthroughs that will cure previously incurable diseases. Accordingly, cell and gene therapy are extremely important areas of future opportunity for MPM, and Mitch is an acknowledged scientific leader in this space. Our portfolio companies will benefit greatly from his expertise, and we are privileged and tremendously grateful that Mitch has elected to share his considerable talents and experience with us and our portfolio.”
"The addition of Mitch to our team caps a momentous half-year of hiring for MPM in which we've added half a dozen new operating partners with expertise ranging from R&D (Mitch and Patrick Baeuerle) to IP (Greg Sieczkiewicz) to clinical development (Briggs Morrison and Pablo Cagnoni) to M&A and licensing (Tony Rosenberg)," said MPM co-founder Ansbert Gadicke.
For three decades, Mitch has focused on regenerative medicine, cancer immunotherapy and cell and gene therapy, helping to advance niche products from product conception through phase III clinical programs.
http://www.businesswire.com/news/home/20150915006799/en/MPM-Capital-appoints-Mitchell-H.-Finer-PhD#.VfjeH50o7vY
No comments:
Post a Comment